From July 30th to 31st,CFSThe 15th Finance and Economics Summit and the 2026 New Quality Productivity Entrepreneurs Conference were held in Shanghai, Haisi Ke YiThe pharmaceutical group received two awards: “2026 Medical Technology Innovation Award” and “2026 Chemical Pharmaceutical Influence Company”.Winning awards is the industry's recognition of Hisico's long-term commitment to a innovation-driven development strategy and its continuous efforts in advancing medical science and industrial upgrading. It also demonstrates Hisico's comprehensive strength and industry influence as a representative enterprise in China's medical innovation sector.

As a year-long thought conference with wide influence in the financial sector, the summit features the theme “Global Perspective, Chinese Resilience”. It brings together experts and scholars from various fields, corporate representatives, and industry pioneers to discuss the development trends of new productive forces and the paths to high-quality enterprise development. The 2026 New Productive Forces Entrepreneurs Conference held concurrently highlights the resilience and creative vitality of Chinese enterprises in the new era by recognizing outstanding entrepreneurs.

At this summit, Hisicor earned the "2026 Medical Technology Innovation Award" and the "2026 Chemical Pharmaceutical Influence Company" titles due to its continuous deepening innovation research capabilities and outstanding contributions in the pharmaceutical industry.

As one of the important representatives of China’s pharmaceutical innovation efforts, Haisco has always adhered to the innovation-driven development strategy. By focusing on unmet clinical needs, Haisco continuously enhances its independent research and development capabilities, accelerates the transformation of innovation results, and promotes the company’s transition from traditional pharmaceuticals to innovative pharmaceuticals. To date, Haisco has launched 26 1-class innovative drug projects, establishing a phased research and development system covering pre-clinical studies, Phase I, Phase II, and Phase III clinical trials, thereby creating a robust and resilient product portfolio.

Five “firsts in the world” independently developed by Hisicore have been approved for market release, including China’s first independently developed intravenous anesthetic with global intellectual property rights—c环泊酚 injection; the world’s first ultra-long-acting oral diabetes medication every two weeks—caoglitin tablets; the world’s first third-generation calcium ion channel regulator without titration—Kligabalin capsules; and the world’s first highly selective drug for pain reliefPeripheral K receptorStimulant – Anruikefen injection; and the world’s first once-daily oral complement factor B (FB) inhibitor, succinic acid spicopan tablets, which was officially approved for market release recently.

Among them,Cycloheximide InjectionAs meThe country possesses innovative intravenous anesthetic drugs with independent intellectual property rights. Since their launch, these drugs have attracted widespread attention in the medical community and industry due to their innovative mechanism and good clinical performance. On May 31 this year, Cilnefopam was approved by the US FDA for market entry in the United States, becoming the first Chinese original innovative intravenous anesthetic drug to reach international markets. This not only represents a historic breakthrough in domestic innovative anesthetics, but also confirms that China's regulatory standards, innovation drug research and development capabilities, and clinical data quality are recognized globally. It has also accumulated valuable experience for more Chengdu innovation achievements to be recognized worldwide.

From laboratory research and development to clinical application, from innovative achievements to benefits for patients, from "Chinese innovation" to "global innovation," the development path of环泊酚 not only demonstrates Haisco's continuous ability to promote innovative pharmaceuticals, but also shows the exploration path of Chinese pharmaceutical companies participating in global pharmaceutical innovation competition through independent research and development.

In the future, Hisicor will continue to focus on clinical needs, emphasizing both innovation and research development as well as technology transfer. With the philosophy of "in China, for the world," it will continuously enhance its core competitiveness and industrial influence, driving the high-quality development of the pharmaceutical and health industry through more high-value innovative achievements.